This is the case in warfarin treatment to regulate blood coagulation, monitored by prothrombin time including corresponding target values, iron therapy (both via the oral and the intravenous route) in the case of functional iron deficiency, supplemental nutrition in the case of albumin deficiency and 1α,25-Dihydroxyvitamin D3 (1,25D3) and calcimimetic drug therapy to treat secondary hyperparathyroidism. This evidence concerns the gene F2 and secondary hyperparathyroidism.